U.S. Stock Night Market Movements

Biodexa Pharmaceuticals fell 12.71% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Stocks with High Trading Volume in the Industry

Moderna rose 0.42% in the night market. Based on recent key news:

1. On August 24, Moderna and Merck jointly announced that their personalized mRNA cancer vaccine achieved its primary endpoint in a Phase III clinical trial for melanoma patients. This news boosted market confidence in the commercialization prospects of its oncology pipeline, leading to a rise in stock price. Source: Zhitong Finance

2. On August 24, Huafu Securities released a research report stating that Moderna and Merck's personalized tumor vaccine achieved its primary endpoint in the postoperative adjuvant Phase III study for melanoma, reducing the risk of recurrence or death by 49%. This breakthrough marks a shift in the paradigm of cancer treatment, strengthening the entire pharmaceutical sector. Source: Global Network Finance

3. On August 24, Barclays raised Moderna's target price, optimistic about the transformative potential of its melanoma vaccine. The stock currently has a market capitalization of approximately $53.3 billion, rated as B. Source: MoneyDJ The pharmaceutical sector is overall strengthening, with a focus on the tumor vaccine field.

Revolution Medicines rose 0.29% in the night market. Based on recent key news:

1. On August 26, Spark analysts rated RVMD stock as neutral, mainly due to weak financial performance, worsening losses, and accelerated cash burn, but strong clinical and regulatory progress, with technical indicators showing a clear upward trend. Market sentiment signals a buy, with a market capitalization of $44.89 billion.

2. On August 25, Revolution plans to advance elironrasib into a Phase III study targeting first-line NSCLC and reported encouraging results from the Phase I/II study of RMC-5127 for treating solid tumors. Despite a market capitalization of about $45 billion and no approved products yet, if daraxonrasib is approved, the investment strategy could yield substantial returns.

3. On August 25, the outcomes of these events will determine whether the current regulatory openings can translate into actual commercial returns. Market sentiment signals a buy, with a market capitalization of $44.89 billion.

Argenx rose 0.75% in the night market. Based on recent news:

1. On August 24, Deutsche Bank downgraded Argenx from buy to hold, although the target price was raised to €925. Analysts believe that the positive results of Vyvgart have been priced in by the market, and while future sales expectations have been slightly raised, the current stock price reflects these factors, leading to stock price volatility.

2. On August 24, MarketBeat reported that Argenx was not included in the list of top five stocks recommended by leading analysts, despite its rating being moderately buy This may have affected investor confidence, leading to stock price fluctuations.

On August 24, a study by the Karolinska Institute in Sweden found that dietary nitrates and iron can improve cardiac metabolic function and prevent fatty liver. This research provides new targets for nutritional interventions in cardiac metabolic diseases and may indirectly affect the market performance of related biotechnology companies. The biotechnology industry has been active recently, and investors need to pay attention to market volatility risks